

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 1, 2022

AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-56036
(Commission
File Number)

83-3299164
(I.R.S. Employer
Identification No.)

111 Sutter Street, Suite 1300, San Francisco, California 94104
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (888) 669-4885

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	AUGX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On March 1, 2022, Augmedix, Inc., a Delaware corporation (the "**Company**"), issued a press release announcing its participation in the upcoming JMP Securities Technology Conference in San Francisco on March 8, 2022 (the "**Event**"). A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

A copy of the presentation entitled "Investor Presentation" to be presented by the Company at the Event is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibits 99.1 and 99.2 are deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated March 1, 2022 announcing participation at the JMP Securities Technology Conference.
99.2	Investor Presentation.
104	Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AUGMEDIX, INC.

Dated: March 8, 2022

By: /s/ Paul Ginocchio
Paul Ginocchio
Chief Financial Officer

March 1, 2022



Augmedix to Participate at the 2022 JMP Securities Technology Conference

SAN FRANCISCO, March 01, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco.

Manny Krakaris, Chief Executive Officer of Augmedix, will be presenting on Tuesday, March 8, 2022, at 11:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investor Relations" section of the company's website at: <https://ir.augmedix.com/news-events/ir-calendar>.

About Augmedix

Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide. The Company's Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes and performs a suite of related data services. These services relieve physicians of administrative burdens to enable more time for patient care. Augmedix's proprietary platform uses automatic speech recognition, natural language processing and clinical datasets to capture the ambient visit conversation and generate a structured medical note. The structured medical note data is then used to deliver additional data services. Quality is assured by trained medical documentation specialists. To learn more about Augmedix, visit augmedix.com.

Investors:

Caroline Paul
Gilmartin Group
investors@augmedix.com

Media:

Kaila Grafeman
Augmedix
pr@augmedix.com



Source: Augmedix Inc



Investor Presentation
JMP Securities Technology Conference
San Francisco
March 8, 2022



Disclaimer

This presentation includes forward-looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company's future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements use words like "believe," "plan," "expect," "intend," "will," "would," "anticipate," "estimate," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain. In light of these uncertainties, and the assumptions underlying the expectations and other forward-looking statements expressed, the forward-looking events and circumstances discussed in the accompanying materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, those factors described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures in subsequent reports filed with the SEC. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's expectations regarding changes in regulatory requirements; the Company's ability to interoperate with the electronic health record systems of its customers; the Company's reliance on vendors; the Company's ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in the Company's business and in the markets in which the Company operates; the Company's ability to further penetrate its existing customer base; the Company's ability to protect and enforce its intellectual property protection and the scope and duration of such protection; developments and projections relating to the Company's competitors and the Company's industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; the impact of current and future laws and regulations; and the impact of the COVID-19 crisis on the Company's business, results of operations and future growth prospects. Past performance is not necessarily indicative of future results. The forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company's views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, undertake to update any of such information or provide additional information as a result of new information or future events or developments.

Introductions



Emmanuel Krakaris
Chief Executive Officer

- 25 years experience
- Joined Augmedix in 2018

Prior experience:



BNP PARIBAS



Streetline



Paul Ginocchio
Chief Financial Officer

- 23 years experience
- Joined Augmedix in 2020

Prior experience:



Brightfield



Deutsche Bank



Augmedix at a Glance



Real-time and asynchronous virtual medical documentation for clinicians



Connect clinicians with Augmedix Ambient Automation Platform through mobile devices and proprietary software



Comprehensive and flexible solution capable of being delivered at scale to >50,000 addressable physicians



Let physicians focus on what matters most: patient care

>\$22M¹
2021 Revenue

122%
Q3 2021 YoY Net Revenue Retention

16
Health Systems Served

5M+
Notes Completed to Date




(1) Q4 2021 figure and related growth rate based on preliminary, unaudited estimates announced on January 31, 2022, and reflects the midpoint of the range expected for Q4 2021. By this presentation, Augmedix is not updating or confirming its prior guidance.

Key Healthcare Macro Tailwinds



Augmedix Eases the EHR Burden on Providers & Creates System Efficiencies



PHYSICIAN

High-Quality Patient Care

AUGMEDIX


Technology & Documentation

Driving a \$6 Billion Market Opportunity for Augmedix




(1) Company estimates out of a total of more than 1.1M U.S. Clinicians.

Real-Time and Asynchronous Offerings Provide Flexibility, Expand the TAM, and Generate a High-Win Rate vs Competitors




Key Customer Wins in 2021 & Early 2022

- ✓ Veterinary ER with multiple follow-on expansions
- ✓ Notes: Competitive win with national oncology provider
- ✓ Live: Competitive win vs asynchronous solution with rural health system
- ✓ Large regional health system in top 10 U.S. city
- ✓ ER pilot with a top 20 health system
- ✓ Partner driven leads becoming larger mix of overall leads




Augmedix Ambient Automation Platform




- **Building Block** approach combines:
 - Automated Speech Recognition
 - Natural Language Processing
 - Clinical Datasets
- **35+** Specialties
- Multiple healthcare settings:
 - Clinic, ER, urgent care, telehealth, inpatient, nursing home
- **500+** problem templates
 - Manages clinician preferences
- Integrates into EHR
- Leverages **metadata** for new services:
 - Chart Prep
 - Coding
 - Health data analytics

Medical Note Data Flow



2021 Financial Summary

Accelerating Revenue Growth



Improving Gross Margins



\$40m gross capital raised in Oct 2021 provides significant operating runway to execute strategy

Note: Fiscal years are audited through December 31, 2020. Quarterly results are unaudited.

(1) Q4 2021 figure and related growth rate based on preliminary, unaudited estimates announced on January 31, 2022, and reflects the midpoint of the range expected for Q4 2021. By this presentation, Augmedix is not updating or confirming its prior guidance.

(2) Q2 2021 excludes one-time benefit from a previous office lease provision.

(3) As of Q3 2021, the Lifetime Value (LTV) of Augmedix Live is calculated by $ARPU / (\text{Annual Churn Percentage}) \times \text{expected contribution margin}$. Customer Acquisition Cost (CAC) is the sales and marketing spend in the previous quarter divided by the number of new clinicians sold in the most recent quarter plus the onboarding costs in the most recent quarter divided by the number of go-lives in the most recent quarter.

(4) As of Q3 2021, Payback period in months is calculated by the expected contribution profit in the first year $\times 12$.

(5) Based on current period revenue including any expansion or new services and is net of contraction or churn compared to the previous period one year ago but excludes revenue from new Health Enterprises for the current period.

Highly Experienced Management Team

 <p>Emmanuel Krakaris Chief Executive Officer</p>	 	 <p>Paul Ginocchio Chief Financial Officer</p>	 
 <p>Sandra Breber Chief Operating Officer</p>	 	 <p>Jonathan Hawkins Chief Revenue Officer</p>	 
 <p>Ian Shakil Co-Founder & Chief Strategy Officer</p>	 	 <p>Saurav Chatterjee Chief Technology Officer</p>	 
 <p>Davin Lundquist, MD Chief Medical Officer</p>	 	 <p>Rashed Noman Country Manager, Bangladesh</p>	 

Investment Highlights

Differentiated and flexible product solutions for virtual documentation:
Ambient, Mobile, Remote, Real-Time & Synchronous

Increasing physician productivity and optimizing reimbursement

Leading health system customer base with high Net Revenue Retention

Attractive scalable business model with compelling unit economics

Building on AI-driven core platform to deliver automated add-ons and drive growth

